- Home
- APLS
as 05-09-2025 9:46am EST
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 2.3B | IPO Year: | 2017 |
| Target Price: | $39.71 | AVG Volume (30 days): | 2.7M |
| Analyst Decision: | Buy | Number of Analysts: | 18 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.80 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.65 - $43.99 | Next Earning Date: | 05-07-2025 |
| Revenue: | $775,839,000 | Revenue Growth: | 48.04% |
| Revenue Growth (this year): | 12.25% | Revenue Growth (next year): | 21.08% |
Stock Insider Trading Activity of Apellis Pharmaceuticals Inc. (APLS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Chopas James George | APLS | VP/Chief Accounting Officer | Mar 17 '25 | Sell | $24.82 | 183 | $4,542.74 | 47,955 | |
| Watson David O. | APLS | General Counsel | Mar 4 '25 | Sell | $25.10 | 5,569 | $139,789.14 | 138,730 | |
| DeLong Mark Jeffrey | APLS | Chief Business & Strat Officer | Feb 11 '25 | Sell | $28.54 | 363 | $10,359.58 | 83,945 |
Latest Apellis Pharmaceuticals Inc. News
APLS Breaking Stock News: Dive into APLS Ticker-Specific Updates for Smart Investing
MT Newswires
a day ago
RBC Cuts Price Target on Apellis Pharmaceuticals to $18 From $21, Keeps Sector Perform Rating
GuruFocus.com
a day ago
Apellis Pharmaceuticals Inc (APLS) Q1 2025 Earnings Call Highlights: Strong Market Leadership ...
Thomson Reuters StreetEvents
a day ago
Q1 2025 Apellis Pharmaceuticals Inc Earnings Call
Motley Fool
2 days ago
Why Apellis Pharmaceuticals Wilted on Wednesday
Zacks
2 days ago
Apellis Pharmaceuticals (APLS) Reports Q1 Earnings: What Key Metrics Have to Say
MT Newswires
2 days ago
Apellis Pharmaceuticals Q1 Loss Widens, Revenue Decreases
Zacks
2 days ago
Apellis Pharmaceuticals, Inc. (APLS) Reports Q1 Loss, Lags Revenue Estimates
GlobeNewswire
2 days ago
Apellis Pharmaceuticals Reports First Quarter 2025 Financial Results
Compare APLS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "APLS Apellis Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.